GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

After several years in the doldrums, pharmaceutical companies and biotechs expect an uptick in dealmaking in 2025, with some ...

Medicare Advantage (MA) insurers Alignment Healthcare and Clover Health both reported increased membership growth ahead of ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

The Hollywood-focused regional bank's pledge follows fellow financial giant JPMorgan Chase's $2 million commitment.

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.

JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco.

It's not just JPMorgan Chase. Across the industry, banks are rethinking their remote-work policies — but experts say it won't ...

Incyte told JP Morgan attendees of plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GVHD.